Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population.
Joseph T MattinglyNeha S PanditEberechukwu OnukwughaPublished in: Infectious diseases and therapy (2019)
The present study describes the total direct health care costs in HIV-HCV co-infected individuals and HCV-only patients in commercially insured health plans. Spending on pharmacy increased as a proportion of total health care costs in both groups. Further clinical and economic evaluations in HCV and/or HIV populations in the US should consider system-level factors related to insurance type when applying to the entire population.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- healthcare
- antiretroviral therapy
- end stage renal disease
- hiv positive
- ejection fraction
- newly diagnosed
- public health
- chronic kidney disease
- hiv infected
- prognostic factors
- hiv testing
- affordable care act
- risk factors
- social media
- patient reported
- climate change
- long term care